DexCom, Inc.
DXCM
Kedudukan dalam Saham
#757
DexCom, Inc. is a medical technology company primarily focused on innovating,... DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Harga Saham
$85.72
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$32.35B
Perubahan (1 hari)
-0.30%
Perubahan (1 tahun)
22.90%
Negara
US
Perdagangan DexCom, Inc. (DXCM)
Kategori
Healthcare
Hasil untuk DexCom, Inc. (DXCM)
Hasil pada Jun 2026 TTM: $4.97B
Menurut laporan kewangan terkini daripada DexCom, Inc., hasil semasa syarikat (TTM) ialah $4.97B. Pada tahun 2024, syarikat memperoleh hasil sebanyak $4.03B peningkatan berbanding hasil pada tahun 2023 iaitu $3.62B. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi DexCom, Inc. dari 2000 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $4.97B | 6.59% |
| 2025 | $4.66B | 15.60% |
| 2024 | $4.03B | 11.34% |
| 2023 | $3.62B | 24.49% |
| 2022 | $2.91B | 18.84% |
| 2021 | $2.45B | 27.08% |
| 2020 | $1.93B | 30.54% |
| 2019 | $1.48B | 43.08% |
| 2018 | $1.03B | 43.58% |
| 2017 | $718.50M | 25.33% |
| 2016 | $573.30M | 42.61% |
| 2015 | $402.00M | 55.09% |
| 2014 | $259.20M | 62.00% |
| 2013 | $160.00M | 60.16% |
| 2012 | $99.90M | 30.99% |
| 2011 | $76.27M | 56.83% |
| 2010 | $48.63M | 63.78% |
| 2009 | $29.69M | 201.82% |
| 2008 | $9.84M | 112.62% |
| 2007 | $4.63M | 113.25% |
| 2006 | $2.17M | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $46.59B | 837.47% |
US
|
|
| $35.48B | 614.08% |
IE
|
|
| $25.84B | 419.94% |
US
|
|
| $21.00B | 322.52% |
US
|
|
| - | - |
DE
|
